Use este identificador para citar ou linkar para este item:
https://www.arca.fiocruz.br/handle/icict/34560
Tipo de documento
ArtigoDireito Autoral
Acesso aberto
Data de embargo
2020-01-06
Objetivos de Desenvolvimento Sustentável
03 Saúde e Bem-EstarColeções
Metadata
Mostrar registro completo
CROSS-REACTIVITY USING CHIMERIC TRYPANOSOMA CRUZI ANTIGENS: DIAGNOSTIC PERFORMANCE IN SETTINGS WHERE CHAGAS DISEASE AND AMERICAN CUTANEOUS OR VISCERAL LEISHMANIASIS ARE COENDEMIC
Doença de Chagas
Reatividade cruzada
Antígenos quiméricos recombinantes
Leishmaniose visceral
Chagas disease
Cross-reactivity
Recombinant chimeric antigens
Visceral leishmaniasis
Autor(es)
Daltro, Ramona Tavares
Leony, Leonardo Maia
Freitas, Natália Erdens Maron
Silva, Ângelo Antônio Oliveira
Santos, Emily Ferreira
Del-Rei, Rodrigo Pimenta
Brito, Maria Edileuza Felinto
Brandão Filho, Sinval Pinto
Gomes, Yara Miranda
Silva, Marcelo Sousa
Donato, Silvia Tavares
Jeronimo, Selma Maria Bezerra
Monteiro, Gloria Regina de Góis
Carvalho, Lucas Pedreira
Magalhães, Andréa Santos
Zanchin, Nilson Ivo Tonin
Celedon, Paola Alejandra Fiorani
Santos, Fred Luciano Neves
Leony, Leonardo Maia
Freitas, Natália Erdens Maron
Silva, Ângelo Antônio Oliveira
Santos, Emily Ferreira
Del-Rei, Rodrigo Pimenta
Brito, Maria Edileuza Felinto
Brandão Filho, Sinval Pinto
Gomes, Yara Miranda
Silva, Marcelo Sousa
Donato, Silvia Tavares
Jeronimo, Selma Maria Bezerra
Monteiro, Gloria Regina de Góis
Carvalho, Lucas Pedreira
Magalhães, Andréa Santos
Zanchin, Nilson Ivo Tonin
Celedon, Paola Alejandra Fiorani
Santos, Fred Luciano Neves
Afiliação
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Faculty of Technology and Sciences of Bahia. Salvador, BA, Brazil.
Fundação Oswaldo Cruz. Instituto Aggeu Magalhães. Recife, PE, Brasil.
Fundação Oswaldo Cruz. Instituto Aggeu Magalhães. Recife, PE, Brasil.
Fundação Oswaldo Cruz. Instituto Aggeu Magalhães. Recife, PE, Brasil.
Federal University of Rio Grande do Norte. Natal, RN, Brazil / Institute of Hygiene and Tropical Medicine. Lisbon, Portugal.
Federal University of Rio Grande do Norte. Natal, RN, Brazil.
Federal University of Rio Grande do Norte. Natal, RN, Brazil.
Federal University of Rio Grande do Norte. Natal, RN, Brazil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Federal University of Bahia. Salvador, BA, Brazil.
Federal University of Bahia. Salvador, BA, Brazil.
Fundação Oswaldo Cruz. Instituto Carlos Chagas. Curitiba, PR, Brasil.
Molecular Biology Institute of Paraná. Curitiba, PR, Brasil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Faculty of Technology and Sciences of Bahia. Salvador, BA, Brazil.
Fundação Oswaldo Cruz. Instituto Aggeu Magalhães. Recife, PE, Brasil.
Fundação Oswaldo Cruz. Instituto Aggeu Magalhães. Recife, PE, Brasil.
Fundação Oswaldo Cruz. Instituto Aggeu Magalhães. Recife, PE, Brasil.
Federal University of Rio Grande do Norte. Natal, RN, Brazil / Institute of Hygiene and Tropical Medicine. Lisbon, Portugal.
Federal University of Rio Grande do Norte. Natal, RN, Brazil.
Federal University of Rio Grande do Norte. Natal, RN, Brazil.
Federal University of Rio Grande do Norte. Natal, RN, Brazil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Federal University of Bahia. Salvador, BA, Brazil.
Federal University of Bahia. Salvador, BA, Brazil.
Fundação Oswaldo Cruz. Instituto Carlos Chagas. Curitiba, PR, Brasil.
Molecular Biology Institute of Paraná. Curitiba, PR, Brasil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Resumo em Inglês
Chimeric T. cruzi antigens have been proposed as a diagnostic tool for chronic Chagas disease (CD) in both settings where Chagas disease is endemic and those where it is not endemic. Antibody response varies in accordance to each T. cruzi strain, presenting challenges to the use of antigens lacking demonstrated cross-reactivity with Leishmania spp. Our group expressed four chimeric proteins (IBMP-8.1, IBMP-8.2, IBMP-8.3, and IBMP-8.4) and previously assessed their diagnostic performance to determine cross-reactivity with Leishmania spp. Here, we validated our findings using serum samples from different Brazilian geographic areas reporting endemic Chagas disease, endemic visceral or American cutaneous leishmaniasis (ACL), or both. Overall, 829 serum samples were evaluated using commercial and IBMP enzyme-linked immunosorbent assays. Due to the absence of a reference assay to diagnosis CD, latent class analysis (LCA) was performed through the use of a statistical model. The incidence of cross-reactivity for ACL-positive samples varied from 0.35% (IBMP-8.3) to 0.70% (IBMP-8.1 and IBMP-8.2). Regarding visceral leishmaniasis (VL)-positive samples, the IBMP-8.2 and IBMP-8.3 antigens cross-reacted with six (3.49%) and with only one sample (0.58%), respectively. No cross-reactivity with either ACL or VL was observed for the IBMP-8.4 antigen. Similarly, no cross-reactions were found when VL-positive samples were assayed with IBMP-8.1. The agreement among the results obtained using IBMP antigens ranged from 97.3% for IBMP-8.2 and 99% for IBMP-8.1 and IBMP-8.3 to 100% for IBMP-8.4, demonstrating almost perfect agreement with LCA. Accordingly, in light of the negligible cross-reactivity with both ACL and VL, we suggest the use of IBMP antigens in regions where T. cruzi and Leishmania spp. are coendemic.
Palavras-chave
Leishmaniose tegumentar americanaDoença de Chagas
Reatividade cruzada
Antígenos quiméricos recombinantes
Leishmaniose visceral
Palavras-chave em inglês
American cutaneous leishmaniasisChagas disease
Cross-reactivity
Recombinant chimeric antigens
Visceral leishmaniasis
Compartilhar